Efficacy and Safety Results From a Pivotal, Phase 3 Study of TrenibotulinumtoxinE for Treatment of Moderate-to-Severe Glabellar Lines in Toxin-Experienced and Toxin-Naive Adults

医学 皱纹 不利影响 安慰剂 患者满意度 临床终点 肉毒神经毒素 随机对照试验 外科 物理疗法 肉毒毒素 临床试验 内科学 疾病严重程度 前额 试用登记 随机化
作者
Cheryl Burgess,Marion Moers-Carpi,Magdalena Boczarska‐Jedynak,Brian S. Biesman,Charles Boyd,Daniela Greiner-Krüger,Deirdre Hooper,Keith A Marcus,Chung-Yi Chiang,Grace S. Park,Sandhya V. Shimoga,Amy S. Weitzenfeld,Joan-En Chang-Lin
出处
期刊:Aesthetic Surgery Journal [Oxford University Press]
标识
DOI:10.1093/asj/sjag198
摘要

BACKGROUND: Glabellar lines (GLs) are commonly treated with botulinum toxins; however, individuals may be hesitant to undergo treatment because of uncertainty around outcomes. OBJECTIVES: This Phase 3, double-blind, placebo-controlled study evaluated the safety and efficacy of trenibotulinumtoxinE (trenibotE), a botulinum neurotoxin serotype E, in toxin-naive and toxin-experienced adults with moderate-to-severe GL. METHODS: Participants were randomized 3:1 to receive either trenibotE (700 U) or placebo. The rigorous, multicomponent, primary endpoint was achieving a Grade 0 or 1 (None or Mild), with ≥2-grade improvement on the Facial Wrinkle Scale (FWS) at maximum frown by investigator and participant assessments on Day 7. Additional endpoints included FWS improvement over time, patient-reported outcomes, and assessments in participants who had appearance-related psychological impacts. Safety was monitored throughout. RESULTS: At Day 7, trenibotE was associated with significantly higher responder rates (60.0%) compared with placebo (0.6%) (P < .0001). Improvements began at Hour 8 (P < .001, unadjusted), peaked at Day 7, and returned to moderate-to-severe GL severity by Day 21. Treatment satisfaction was higher following trenibotE at Hour 8 (33.0% vs 13.8%; P < .0001, unadjusted), Hour 24 (59.2% vs 17.3%; P < .0001), and Day 7 (77.6% vs 5.1%). Higher satisfaction with natural-looking results following trenibotE treatment was first observed at Hour 8 (P < .0001, unadjusted) and peaked at Day 7 (78.5% vs 9.0% placebo; P < .0001). Most adverse events were mild, nonserious, and unrelated to study treatment. CONCLUSIONS: TrenibotE significantly improved GL severity with rapid results and short duration of effect. Participants reported high satisfaction with treatment and natural-looking results. The overall benefit-risk profile was favorable. LEVEL OF EVIDENCE: 1 (RISK): For image description, please refer to the figure legend and surrounding text.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
如意葶完成签到 ,获得积分10
1秒前
小螃蟹大大王完成签到 ,获得积分10
1秒前
xiong xiong完成签到,获得积分10
1秒前
自由飞翔完成签到,获得积分10
4秒前
雷霆大香蕉完成签到,获得积分10
7秒前
木香完成签到,获得积分10
7秒前
无限翅膀完成签到,获得积分10
7秒前
闲情偶寄完成签到,获得积分10
7秒前
kaiqiang完成签到,获得积分0
8秒前
8秒前
Orange的应助被天马采纳,获得10
8秒前
kk完成签到,获得积分10
9秒前
忍者泡的茶完成签到 ,获得积分10
10秒前
聪明的心语完成签到,获得积分10
10秒前
自由飞翔发布了新的文献求助10
11秒前
hkkogcu7449oi完成签到,获得积分10
11秒前
11秒前
SMLW完成签到,获得积分10
11秒前
SuYuo完成签到,获得积分10
12秒前
Hexazine完成签到,获得积分10
12秒前
昵称完成签到,获得积分10
12秒前
Muccio完成签到 ,获得积分10
13秒前
guopan完成签到,获得积分10
13秒前
今年我必胖20斤完成签到,获得积分10
14秒前
韭菜盒子完成签到,获得积分20
14秒前
YX1994完成签到,获得积分10
14秒前
jian94完成签到,获得积分10
14秒前
龙2024完成签到,获得积分10
15秒前
淡定的幼晴完成签到,获得积分10
15秒前
raditivecooling完成签到,获得积分10
15秒前
我谈完成签到,获得积分10
16秒前
良善小韩皮完成签到,获得积分10
16秒前
Keyuuu30完成签到,获得积分0
18秒前
愉快的丹彤完成签到 ,获得积分10
18秒前
Lisa完成签到,获得积分10
18秒前
zzgpku完成签到,获得积分0
18秒前
搞怪妖妖完成签到 ,获得积分10
19秒前
在下厉飞雨完成签到 ,获得积分10
19秒前
丨墨月丨完成签到,获得积分0
19秒前
辛勤的囧完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428